MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

NCT06904261 ·Status: RECRUITING ·Phase: PHASE3

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

NCT04049760 ·Status: COMPLETED ·Phase: PHASE3

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283959 ·Status: COMPLETED ·Phase: PHASE2

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

NCT00304512 ·Status: COMPLETED ·Phase: PHASE2

Home Therapy With Replagal in Fabry Disease

NCT01355146 ·Status: COMPLETED

A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283933 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

NCT03425539 ·Status: COMPLETED ·Phase: PHASE3

A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00214500 ·Status: COMPLETED ·Phase: PHASE2

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

NCT03500094 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Phase 3 Long-Term Safety Study of Migalastat

NCT01458119 ·Status: TERMINATED ·Phase: PHASE3

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

NCT00925301 ·Status: COMPLETED ·Phase: PHASE3

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

NCT04252066 ·Status: RECRUITING

Sophisticated Assessment of Disease Burden in Patients With Fabry Disease

NCT01210196 ·Status: COMPLETED

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

NCT01298141 ·Status: COMPLETED ·Phase: PHASE3

Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

NCT00319046 ·Status: COMPLETED ·Phase: PHASE3

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742 ·Status: RECRUITING

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

NCT00526071 ·Status: TERMINATED ·Phase: PHASE2

A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease

NCT02930655 ·Status: COMPLETED ·Phase: PHASE1

Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

NCT05698901 ·Status: RECRUITING

Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

NCT04552691 ·Status: APPROVED_FOR_MARKETING

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

NCT06663358 ·Status: RECRUITING

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

NCT01218659 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

NCT03737214 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Fabry and Cardiomyopathy (FaCard)

NCT01429597 ·Status: WITHDRAWN

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

NCT01196871 ·Status: COMPLETED ·Phase: PHASE2